Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22735384

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2012 Jul 28
First author
Hauschild A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2012 Jul 28;380(9839):320-2. doi: 10.1016/S0140-6736(12)60993-3.
    note
    Source null
    related pmid
    22735383
    relationship
    Comment in
  2. citation
    Br J Dermatol. 2013 Mar;168(3):467-70; discussion 470-1. doi: 10.1111/bjd.12238.
    note
    Source null
    related pmid
    23445310
    relationship
    Comment in

Authors and identifiers

  1. name
    Hauschild A
    type
    Author
  2. name
    Grob JJ
    type
    Author
  3. name
    Demidov LV
    type
    Author
  4. name
    Jouary T
    type
    Author
  5. name
    Gutzmer R
    type
    Author
  6. name
    Millward M
    type
    Author
  7. name
    Rutkowski P
    type
    Author
  8. name
    Blank CU
    type
    Author
  9. name
    Miller WH Jr
    type
    Author
  10. name
    Kaempgen E
    type
    Author
  11. name
    Martín-Algarra S
    type
    Author
  12. name
    Karaszewska B
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Hauschild A
    type
    Author
  2. name
    Grob JJ
    type
    Author
  3. name
    Demidov LV
    type
    Author
  4. name
    Jouary T
    type
    Author
  5. name
    Gutzmer R
    type
    Author
  6. name
    Millward M
    type
    Author
  7. name
    Rutkowski P
    type
    Author
  8. name
    Blank CU
    type
    Author
  9. name
    Miller WH Jr
    type
    Author
  10. name
    Kaempgen E
    type
    Author
  11. name
    Martín-Algarra S
    type
    Author
  12. name
    Karaszewska B
    type
    Author
bibliography ids
  1. nci-bib-102fd3196ec18031763b7004
book metadata
content sha256
7f9168b2f52aec2c250effdf76df03ee89f1a972c5d8a778f67ed3cad628f762
document type
citation
dois
  1. 10.1016/S0140-6736(12)60868-X
electronic publication date
display
2012 Jun 25
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:22735384
immutable id
pubmed:22735384@7f9168b2f52aec2c250effdf76df03ee89f1a972c5d8a778f67ed3cad628f762
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9839
name
Lancet (London, England)
nlm unique id
2985213R
pages
358-65
volume
380
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2012 Jul 28;380(9839):320-2. doi: 10.1016/S0140-6736(12)60993-3.
    note
    Source null
    related pmid
    22735383
    relationship
    Comment in
  2. citation
    Br J Dermatol. 2013 Mar;168(3):467-70; discussion 470-1. doi: 10.1111/bjd.12238.
    note
    Source null
    related pmid
    23445310
    relationship
    Comment in
outcomes validated
false
pmid
22735384
provenance
batch id
1e3045de9f47a5ccd566
provider
NCBI PubMed ESummary
record sha256
c130ace707a72ee96e67f267268faf0e279b976d76369db1de51b50d112175ef
response sha256
0c42e87ee821aef9d804e2d77dfdba8876f375111db163986dd22ba43a3d6a52
retrieved at
2026-09-09T23:46:50.128287+00:00
publication date
display
2012 Jul 28
precision
day
year
2012
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22735384/
title
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Preserved source evidence · Not medical advice